Takayuki Ohguri1, Yoko Harima2, Hajime Imada3, Hideyuki Sakurai4, Tatsuya Ohno5, Yoshiyuki Hiraki6, Koh Tuji7, Masahiro Tanaka8, Hiromi Terashima9. 1. a Department of Radiology , University of Occupational and Environmental Health , Kitakyusyu City , Japan. 2. b Department of Radiology , Kansai Medical University , Moriguchi City , Japan. 3. c Cancer Therapy Centre, Tobata Kyoritsu Hospital , Kitakyusyu City , Japan. 4. d Department of Radiation Oncology , University of Tsukuba , Tsukuba City , Japan. 5. e Department of Radiation Oncology , Gunma University Heavy Ion Medical Centre , Maehashi City , Japan. 6. f Department of Radiology , National Hospital Organization Kagoshima Medical Centre , Kagoshima City , Japan. 7. g Department of Radiology , National Hospital Organization Minami Wakayama Medical Centre , Tanabe City , Japan. 8. h Department of Radiation Oncology , Osaka City General Hospital , Osaka City , Japan. 9. i Department of Radiology , Harasanshin Hospital , Fukuoka City , Japan.
Abstract
PURPOSE: To evaluate the contribution of the thermal dose parameters during regional hyperthermia (HT) treatment to the clinical outcomes in patients with cervical carcinoma (CC) who receivedchemoradiotherapy (CRT) plus HT. MATERIALS AND METHODS: Data from a multicentre randomised clinical trial of concurrent CRT + HT vs. CRT alone were used to evaluate the efficacy and safety of this combination therapy in the CC patients. The intrarectal temperatures of patients undergoing HT were recorded. The complete thermal data of 47 (92%) of the 51 patients in the CRT + HT group were available for the thermal analysis. Thus, 47 patients who received CRT + HT were included in the present study. RESULTS: Among the patients who received CRT + HT, a higher CEM43T90 (≥1 min) value (a thermal dose parameter) was significantly associated with better local relapse-free survival in both univariate (p = 0.024) and multivariate (p = 0.0097) analyses. The disease-free survival of the patients with higher CEM43T90 (≥1 min) values tended to be better in comparison to patients with lower CEM43T90 (<1 min) value (p = 0.071). A complete response tended to be associated with the CEM43T90 (p = 0.056). Disease-free survival, local relapse-free survival and complete response rate for patients with higher CEM43T90 (≥1) were significantly better than those for patients with CRT alone (p = 0.036, p = 0.036 and p = 0.048). CONCLUSIONS: Dose-effect relationships between thermal dose parameters and clinical outcomes were confirmed in the CC patients treated with a combination of CRT + HT. This study also confirmed that HT with lower CEM43T90 is insufficient to achieve a significant hyperthermic sensitisation to CRT.
RCT Entities:
PURPOSE: To evaluate the contribution of the thermal dose parameters during regional hyperthermia (HT) treatment to the clinical outcomes in patients with cervical carcinoma (CC) who received chemoradiotherapy (CRT) plus HT. MATERIALS AND METHODS: Data from a multicentre randomised clinical trial of concurrent CRT + HT vs. CRT alone were used to evaluate the efficacy and safety of this combination therapy in the CC patients. The intrarectal temperatures of patients undergoing HT were recorded. The complete thermal data of 47 (92%) of the 51 patients in the CRT + HT group were available for the thermal analysis. Thus, 47 patients who received CRT + HT were included in the present study. RESULTS: Among the patients who received CRT + HT, a higher CEM43T90 (≥1 min) value (a thermal dose parameter) was significantly associated with better local relapse-free survival in both univariate (p = 0.024) and multivariate (p = 0.0097) analyses. The disease-free survival of the patients with higher CEM43T90 (≥1 min) values tended to be better in comparison to patients with lower CEM43T90 (<1 min) value (p = 0.071). A complete response tended to be associated with the CEM43T90 (p = 0.056). Disease-free survival, local relapse-free survival and complete response rate for patients with higher CEM43T90 (≥1) were significantly better than those for patients with CRT alone (p = 0.036, p = 0.036 and p = 0.048). CONCLUSIONS: Dose-effect relationships between thermal dose parameters and clinical outcomes were confirmed in the CC patients treated with a combination of CRT + HT. This study also confirmed that HT with lower CEM43T90 is insufficient to achieve a significant hyperthermic sensitisation to CRT.
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Lifei Zhu; Ari Partanen; Michael R Talcott; H Michael Gach; Suellen C Greco; Lauren E Henke; Jessika A Contreras; Imran Zoberi; Dennis E Hallahan; Hong Chen; Michael B Altman Journal: Int J Hyperthermia Date: 2019 Impact factor: 3.914
Authors: Marloes IJff; Bregje van Oorschot; Arlene L Oei; Przemek M Krawczyk; Hans M Rodermond; Lukas J A Stalpers; H Petra Kok; Johannes Crezee; Nicolaas A P Franken Journal: Int J Mol Sci Date: 2018-08-16 Impact factor: 5.923